Current approaches for absorption, distribution, metabolism, and excretion characterization of antibody-drug conjugates: An industry white paper

Drug Metabolism and Disposition

Volumn 44, Issue 5, 2016, Pages 617-623

  Kraynov, Eugenia ^a   Kamath, Amrita V ^b   Walles, Markus ^c   Tarcsa, Edit ^d   Deslandes, Antoine ^e   Iyer, Ramaswamy A ^f   Datta Mannan, Amita ^g   Sriraman, Priya ^h   Bairlein, Michaela ⁱ   Yang, Johnny J ^j   Barfield, Matthew ^k   Xiao, Guangqing ^l   Escandon, Enrique ^m   Wang, Weirong ⁿ   Rock, Dan A ^o   Chemuturi, Nagendra V ^p   Moore, David J ^q  

^a PFIZER INC   (United States)

^b GENENTECH INC   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d ABBVIE INC   (United States)

^e SANOFI   (France)

^f BRISTOL MYERS SQUIBB   (United States)

^g ELI LILLY AND COMPANY   (United States)

^h CELGENE CORPORATION   (United States)

ⁱ BAYER PHARMA AG   (Germany)

^j TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^k GLAXOSMITHKLINE   (United Kingdom)

^l BIOGEN   (United States)

^m MERCK RESEARCH LABORATORIES   (United States)

ⁿ Janssen R and D US   (United States)

^o AMGEN INC   (United States)

^p SEATTLE GENETICS INC   (United States)

^q Roche Innovation Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; CYTOCHROME P450; DRUG ANTIBODY; FC RECEPTOR; GLUCURONOSYLTRANSFERASE; LYSOSOME ENZYME; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; DRUG;

BINDING AFFINITY; CANCER CELL; CATABOLISM; CELL MEMBRANE PERMEABILITY; DRUG ABSORPTION; DRUG ANTIBODY RATIO; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG SCREENING; DRUG STABILITY; DRUG TISSUE LEVEL; DRUG UPTAKE; HUMAN; IN VITRO STUDY; LIVER CELL; LIVER MICROSOME; NONHUMAN; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PINOCYTOSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMIC CIRCULATION; TISSUE DISTRIBUTION; ANIMAL; DRUG INDUSTRY; METABOLISM; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG INDUSTRY; HUMANS; IMMUNOCONJUGATES; PHARMACEUTICAL PREPARATIONS;

EID: 84963814117     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.068049     Document Type: Review

References (31)

1. Adair JR, Howard PW, Hartley JA, Williams DG, and Chester KA (2012) Antibody-drug conjugates - A perfect synergy. Expert Opin Biol Ther 12:1191-1206.
2. Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, and Senter PD (2008) Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem 19:759-765.
3. Alley SC, Okeley NM, and Senter PD (2010) Antibody-drug conjugates: Targeted drug delivery for cancer. Curr Opin Chem Biol 14:529-537.
4. Alley SC, Zhang X, Okeley NM, Anderson M, Law CL, Senter PD, and Benjamin DR (2009) The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther 330: 932-938.
5. Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle NR, Kozak KR, Fourie A, Chuh J, Koppada N, and Saad O, et al. (2011) Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem 22: 1994-2004.
6. Carrasco-Triguero M, Yi JH, Dere R, Qiu ZJ, Lei C, Li Y, Mahood C, Wang B, Leipold D, and Poon KA, et al. (2013) Immunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. Bioanalysis 5:1007-1023.
7. Deslandes A (2014) Comparative clinical pharmacokinetics of antibody-drug conjugates in firstin- human Phase 1 studies. MAbs 6:859-870.
8. Erickson HK and Lambert JM (2012) ADME of antibody-maytansinoid conjugates. AAPS J 14: 799-805.
9. Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano CA, Mai E, Johnson HA, Gunter B, Audette CA, Gupta M, and Pinkas J, et al. (2012) The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther 11:1133-1142.
10. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, and Zabinski RF, et al. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10:7063-7070.
11. Han TH and Zhao B (2014) Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates. Drug Metab Dispos 42:1914-1920.
12. Hengel SM, Sanderson R, Valliere-Douglass J, Nicholas N, Leiske C, and Alley SC (2014) Measurement of in vivo drug load distribution of cysteine-linked antibody-drug conjugates using microscale liquid chromatography mass spectrometry. Anal Chem 86:3420-3425.
13. Gorovits B (2015) Bioanalysis of antibody-drug conjugates. Bioanalysis 7:1559-1560.
14. Gorovits B, Alley SC, Bilic S, Booth B, Kaur S, Oldfield P, Purushothama S, Rao C, Shord S, and Siguenza P (2013) Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis 5:997-1006.
15. Kamath AV and Iyer S (2015) Preclinical pharmacokinetic considerations for the development of antibody drug conjugates. Pharm Res 32:3470-3479.
16. Kaur S, Xu K, Saad OM, Dere RC, and Carrasco-Triguero M (2013) Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis 5:201-226.
17. Kumar S, King LE, Clark TH, and Gorovits B (2015) Antibody-drug conjugates nonclinical support: from early to late nonclinical bioanalysis using ligand-binding assays. Bioanalysis 7: 1605-1617.
18. Lin K and Tibbitts J (2012) Pharmacokinetic considerations for antibody drug conjugates. Pharm Res 29:2354-2366.
19. Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, Jonas M, Anderson ME, Setter JR, and Senter PD (2015) Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol 33:733-735.
20. Myler H, Rangan VS, Wang J, Kozhich A, Cummings JA, Neely R, Dail D, Liu A, Wang B, and Vezina HE, et al. (2015) An integrated multiplatform bioanalytical strategy for antibodydrug conjugates: a novel case study. Bioanalysis 7:1569-1582.
21. Rodríguez-Antona C, Donato MT, Boobis A, Edwards RJ, Watts PS, Castell JV, and Gómez- Lechón MJ (2002) Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 32: 505-520.
22. Roopenian DC and Akilesh S (2007) FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 7:715-725.
23. Saad OM, Shen BQ, Xu K, Khojasteh SC, Girish S, and Kaur S (2015) Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates. Bioanalysis 7:1583-1604.
24. Saber H and Leighton JK (2015) An FDA oncology analysis of antibody-drug conjugates. Regul Toxicol Pharmacol 71:444-452.
25. Sapra P, Hooper AT, O'Donnell CJ, and Gerber HP (2011) Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs 20:1131-1149.
26. Senter PD (2009) Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 13: 235-244.
27. Shen BQ, Bumbaca D, Saad O, Yue Q, Pastuskovas CV, Khojasteh SC, Tibbitts J, Kaur S, Wang B, and Chu YW, et al. (2012a) Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab 13:901-910.
28. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, and Mai E, et al. (2012b) Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 30:184-189.
29. Singh AP, Shin YG, and Shah DK (2015) Application of pharmacokinetic-pharmacodynamic modeling and simulation for antibody-drug conjugate development. Pharm Res 32:3508-3525.
30. Xu K, Liu L, Dere R, Mai E, Erickson R, Hendricks A, Lin K, Junutula JR, and Kaur S (2013) Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum. Bioanalysis 5:1057-1071.
31. Zahreddine HA and Borden KL (2015) Molecular pathways: GLI1-induced drug glucuronidation in resistant cancer cells. Clin Cancer Res 21:2207-2210.